From GlobeNewswire.:

Cognition Therapeutics, Inc. announced the closing of its public offering, selling 6,571,428 shares of common stock at $1.75 per share, raising approximately $11.5 million. The proceeds will fund research, clinical development, and manufacturing of product candidates to treat neurodegenerative disorders. Titan Partners Group managed the offering, made under an effective shelf registration statement. Interested parties can access the prospectus on the SEC website or by contacting Titan Partners Group. Cognition focuses on developing small molecule therapeutics for age-related central nervous system disorders. The company believes targeting the σ-2 receptor with CT1812 provides a unique approach to treating degenerative diseases.



Read more at GlobeNewswire.: Cognition Therapeutics Announces Closing of $11.5 Million